Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults Publication Population Pharmacokinetics of Azithromycin in Whole Blood, Peripheral Blood Mononuclear Cells, and Polymorphonuclear Cells in Healthy Adults Azithromycin's extensive distribution to proinflammatory cells, including peripheral blood mononuclear cells (PBMCs) and polymorphonuclear cells…CertaraMarch 5, 2014
Impact of Electrocardiographic Data Quality on Moxifloxacin Response in Thorough QT/QTc Studies Publication Impact of Electrocardiographic Data Quality on Moxifloxacin Response in Thorough QT/QTc Studies Thorough QT studies are typically conducted for drugs with systemic bioavailability and include a positive…CertaraMarch 1, 2014
Electrocardiographic Data Quality in Thorough QT/QTc Studies Publication Electrocardiographic Data Quality in Thorough QT/QTc Studies Most drugs with systemic bioavailability have to undergo a thorough QT (TQT) study, which includes…CertaraMarch 1, 2014
In Vitro-In Vivo Extrapolation of Drug-induced Proarrhythmia Predictions at the Population Level Publication In Vitro-In Vivo Extrapolation of Drug-induced Proarrhythmia Predictions at the Population Level Drug cardiotoxicity is a serious issue for patients, regulators, pharmaceutical companies and health service payers…CertaraMarch 1, 2014
Precision Criteria to Derive Sample Size When Designing Pediatric Pharmacokinetics Studies: Which Measure of Variability Should be Used? Publication Precision Criteria to Derive Sample Size When Designing Pediatric Pharmacokinetics Studies: Which Measure of Variability Should be Used? A new approach for calculation of sample size in pediatric clinical pharmacokinetic studies was suggested based on desired precision for a pharmacokinetic parameter…CertaraMarch 1, 2014
Population Pharmacokinetic Analysis of Axitinib in Healthy Volunteers Publication Population Pharmacokinetic Analysis of Axitinib in Healthy Volunteers Axitinib is a potent and selective second generation inhibitor of vascular endothelial growth factor receptors…CertaraFebruary 21, 2014
A Model-based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-malignant Pain Publication A Model-based Meta-analysis to Compare Efficacy and Tolerability of Tramadol and Tapentadol for the Treatment of Chronic Non-malignant Pain Pain is a major symptom in many medical conditions which can be relieved thanks to…CertaraFebruary 13, 2014
A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain Publication A Systems Pharmacology Perspective on the Clinical Development of Fatty Acid Amide Hydrolase Inhibitors for Pain The level of the endocannabinoid anandamide is controlled by fatty acid amide hydrolase (FAAH). In…CertaraJanuary 15, 2014
The IQ-CSRC Prospective Clinical Phase 1 Study: Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study? Publication The IQ-CSRC Prospective Clinical Phase 1 Study: Can Early QT Assessment Using Exposure Response Analysis Replace the Thorough QT Study? A collaboration between the Consortium for Innovation and Quality in Pharmaceutical Development and the Cardiac…CertaraJanuary 1, 2014
Incorporating Target Shedding into a Minimal PBPK-TMDD Model for Monoclonal Antibodies Publication Incorporating Target Shedding into a Minimal PBPK-TMDD Model for Monoclonal Antibodies Shedding of a pharmacological target from cells, giving rise to a soluble target that can also bind therapeutic proteins, is…CertaraJanuary 1, 2014